Zika virus (ZIKV) is currently undergoing pandemic emergence. While disease is typically subclinical, severe neurologic manifestations in fetuses and newborns after congenital infection underscore an urgent need for antiviral interventions. The adenosine analog BCX4430 has broad-spectrum activity against a wide range of RNA viruses, including potent in vivo activity against yellow fever, Marburg and Ebola viruses. We tested this compound against African and Asian lineage ZIKV in cytopathic effect inhibition and virus yield reduction assays in various cell lines. To further evaluate the efficacy in a relevant animal model, we developed a mouse model of severe ZIKV infection, which recapitulates various human disease manifestations including peripheral virus replication, conjunctivitis, encephalitis and myelitis. Time-course quantification of viral RNA accumulation demonstrated robust viral replication in several relevant tissues, including high and persistent viral loads observed in the brain and testis. The presence of viral RNA in various tissues was confirmed by an infectious culture assay as well as immunohistochemical staining of tissue sections. Treatment of ZIKV-infected mice with BCX4430 significantly improved outcome even when treatment was initiated during the peak of viremia. The demonstration of potent activity of BCX4430 against ZIKV in a lethal mouse model warrant its continued clinical development.
Zika virus (ZIKV) is an emerging mosquito-borne flavivirus that typically results in either subclinical infection or a mild disease characterized by headache, conjunctivitis, fever, rash and arthralgia (Gatherer and Kohl, 2015; Ramos da Silva and Gao, 2016) . ZIKV is rapidly spreading throughout the Americas, infecting millions of people in many different countries. More serious illness, including congenital neurologic syndromes and severe Guillain-Barre syndrome, has been associated with recent ZIKV outbreaks (Araujo et al., 2016; ). Microcephaly appears to be the most dramatic and severe outcome among a spectrum of congenital ZIKV infection neurologic deficits that are associated with ZIKV infection during pregnancy de Fatima Vasco Aragao et al., 2016) . In cases of congenital microcephaly, ZIKV has been detected in the placenta, amniotic fluid, cerebrospinal fluid and fetal brain tissue (Cordeiro et al., 2016; Driggers et al., 2016; Mlakar et al., 2016; Noronha et al., 2016) and there is little doubt that ZIKV infection during pregnancy can result in profound neurologic damage to the fetus (Rasmussen et al., 2016) . The World Health Organization has concluded that ZIKV infections constitute a public health emergency of international concern. Countermeasures for the treatment or prevention of ZIKV disease are desperately needed.
Developing an antiviral drug for treatment during pregnancy presents substantial challenges arising from justified concerns for the wellbeing of the mother and her developing fetus. Several precedents exist for treatment during pregnancy in the human immunodeficiency virus (HIV) field (Brocklehurst and Volmink, 2002) . In addition to the obvious desirability of safe and effective treatment of ZIKV infection in pregnant women, men shedding infectious ZIKV in semen have the potential to transmit the virus to their sexual partners and represent another high-priority target population for effective interventions. Patients experiencing Guillain-Barre syndrome (GBS) are another target group for the development of antiviral interventions (Dirlikov et al., 2016) , although virus involvement in GBS remains to be determined.
The small molecule drug candidate BCX4430 is an adenosine nucleoside analog that functions as a selective inhibitor of viral RNA-dependent RNA polymerase (Warren et al., 2014) that is currently in clinical stage development. Broad-spectrum activity against various RNA viruses in cell culture has been reported (Warren et al., 2014) . BCX4430 is highly active in a hamster model of yellow fever virus (YFV) disease, with efficacy demonstrated even when administered once viremia and hepatitis were established (Julander et al., 2014) . Potent activity has also been reported in a mouse models of Ebola (EBOV) and Marburg virus (MARV) diseases, and a lethal non-human primate model of MARV disease (Warren et al., 2014) . Because of its broad-spectrum activity and efficacy against a related flavivirus, YFV, BCX4430 was investigated for antiviral efficacy against ZIKV.
Various mouse models have been developed for the study of ZIKV infection (Aliota et al., 2016; Dowall et al., 2016; Li et al., 2016; Miner et al., 2016; Rossi et al., 2016; Wu et al., 2016; Zmurko et al., 2016) . Because wild-type mice typically clear ZIKV rapidly following inoculation and do not develop serious illness, many researchers have employed various mouse strains lacking type 1 interferon (IFN) function. The IFN regulatory system is critical for resistance to ZIKV infection in mice and differential disease severity was observed when IFN receptors were removed or blocked Yockey et al., 2016) . The importance of the IFN pathway was further delineated when ZIKV-infected SCID mice, lacking T and B lymphocytes, were shown to have an extended survival time (average of 26 days longer) as compared with IFN-receptor deficient mice (Zmurko et al., 2016) . Mice that lack type I and II IFN receptors (AG129 mice) are highly susceptible to ZIKV infection and display relevant signs of disease (Zmurko et al., 2016) .
We describe herein the activity of BCX4430 in both cell culture and an AG129 mouse model of ZIKV infection characterized by viral encephalomyelitis. These data provide proof-of-principle for the use of BCX4430 in the treatment of ZIKV and justification for the further development of this nucleoside analog.
Materials and methods

Animals
Male and female AG129 mice, lacking IFN-a/b and -g receptors, were bred under germ-free conditions in an in-house breeding colony. Mice between 8 and 10 weeks with an average weight of 22 g were used. Animals were assigned to groups and individually marked with ear tags.
Test articles
BCX4430 dihydrochloride was supplied as a powder by BioCryst Pharmaceuticals, Inc. Treatment doses reported herein represent the concentration of the dihydrochloride, which contains 64% BCX4430. Ribavirin was provided by the former ICN Pharmaceuticals, Inc. Compounds were prepared in minimal essential medium (MEM) or sterile saline for cell culture and animal studies, respectively.
Viruses
The MR-766 isolate of ZIKV was collected from a sentinel rhesus monkey in the Zika forest of Uganda in April 1947 and the P 6-740 strain was collected from mosquitos in Malaysia in July 1966. These two ZIKV strains were provided by Robert B. Tesh (University of Texas Medical Branch, Galveston, TX). The ZIKV PRVABC-59 strain was isolated in Puerto Rico from the blood of a human patient in December 2015. The virus was provided by Barbara Johnson (Centers for Disease Control and Prevention, Fort Collins, CO). Virus strains were amplified once or twice in Vero76 cells and had titers of 10 7.7 , 10 6.7 and 10 7.5 50% cell culture infectious doses (CCID 50 )/mL for MR-766, P 6-740 and PRVABC-59, respectively. The Malaysian P 6-740 strain was titrated for lethality in AG129 mice and used for the present animal study.
In vitro evaluation of compounds
The antiviral activity of BCX4430 and ribavirin were evaluated in vitro by cytopathic effect (CPE) inhibition assays. Various cell lines, including Vero76, Huh7 and RD, were used for evaluation of antiviral effects. Compounds were prepared in MEM just prior to testing. Inhibition of virus replication was determined by microscopic examination of the infected cells for cytopathic effect, increase of neutral red (NR) dye uptake (colorimetric determination), and virus yield reduction. Uninfected cells treated with a compound were assayed as above for cytotoxicity control.
Real-time RT-PCR for the detection of ZIKV RNA
Fifty to 100 mg of freshly isolated tissue was ground with a pestle in 1 mL TRI Reagent (Sigma-Aldrich, St. Louis, MO) and total RNA was extracted. For the extraction of viral RNA from serum, QIAamp Viral RNA Mini Spin kit was used according to the manufacturer's instructions (Qiagen, Valencia, CA). Extracted RNA was eluted with nuclease-free water and was amplified by a quantitative real-time RT-PCR using the Logix Smart Zika Test developed by Co-Diagnostics, Inc. (Bountiful, UT). Five mL of the master mix containing a set of primers and Rapid Probe, labeled with a FAM fluorophore and DABCYL quencher, was mixed with 2e5 mL of RNA and an appropriate volume of water for a final reaction volume of 10 ml. RNA was first reverse transcribed for 10 min at 55 C, followed by strand separation by heating to 95 C for 20 s. The PCR reaction consisted of 40 cycles at 95 C for 1 s and 55 C for 20 s. A standard curve was generated with a synthetic RNA spanning the region of amplification and it was used to calculate the number of genome equivalents of the unknown samples.
Infectious assay
Freshly isolated tissues were homogenized in 1:3 (wt/vol) of MEM in a Stomacher bag and stored at À80 C. A 1:10 starting dilution was made and serial dilutions were then prepared and added to a 96-well cell culture dish seeded for 90% confluency with Vero cells. Plates were incubated at 37 C for 5 days and fixed with 4% paraformaldehyde (Sigma-Aldrich). Immunohistochemistry was performed using an anti-flavivirus group antigen antibody (EMD Millipore, Temecula, CA) as described below.
Immunohistochemistry
Two to 4 pups from each litter were prepared for histology and immunohistochemistry (IHC). Whole pups with placentas were placed in freshly. prepared 4% paraformaldehyde. Twenty-four hours later the tissues were rinsed once in phosphate-buffered saline and placed in 70% ethanol. Paraffin-embedded tissues were sectioned (5e8 mm) and processed for hematoxylin-eosin (HE) staining and IHC. Following de-parafinization, the sections were blocked with normal goat serum for 60 min at room temperature. Either a rabbit anti-ZIKV polyclonal antibody (IBT Bioservices, Gaithersburg, MD), mouse anti-flavivirus group antigen monoclonal antibody (EMD Millipore), or mouse monoclonal antibody directed against ZIKV E or NS1 protein (Aalto Bio Reagents, Dublin, Ireland) was incubated with the tissues over-night. An Alexa-flour conjugated secondary antibody (ThermoFisher Scientific, Waltham, MA) was then added and incubated for 2 h. For the infectious assay, horseradish peroxidase conjugated secondary antibodies (Sigma-Aldrich) were then incubated for 2 h, followed by reaction development using a peroxidase substrate kit (Vector Laboratories Inc., Burlingame, CA). Images were captured using Zeiss microscope, AxioVision 4.0.1 and processed using Adobe Photoshop.
Experimental design
A mouse model of ZIKV infection and disease was characterized. Male and female AG129 mice between 8 and 10 weeks were infected subcutaneously (s.c.) with ZIKV (P 6-740). A dose titration of virus was performed to determine a suitable challenge dose of virus for model characterization and antiviral/vaccine studies.
A model characterization study was conducted to identify key time-points of virus replication in various tissues. A cohort of animals was included where survival and weight were monitored to demonstrate consistency with these parameters. Two male and two female mice were necropsied 1, 3, 5, 7, 9, 11 and 13 days after virus challenge. Tissues, including spleen, liver, kidney, brain, and testes/ uterus were collected from each animal. Part of each tissue was fixed in 4% paraformaldehyde or neutral buffered formalin for at least 24 h prior to paraffin embedding and sectioning for use in immunohistochemistry analysis described above. Serum and urine were sampled on the same days from a cohort of animals that were infected in parallel for analysis of viral RNA. Total RNA was extracted from tissues and ZIKV RNA was quantified as described above.
For ZIKV infection and antiviral treatment studies, mice were randomly assigned to groups of 10 animals each. A 10 À3 dilution (10 4.0 pfu/mL) of the virus was prepared in MEM. Mice were challenged s.c. with 0.1 mL of the diluted virus (~10 3.0 pfu/animal). All compound dosages were based on an average mouse weight of 22 g. Compounds were prepared in sterile saline less than 18 h prior to initial administration in mice and stored at 4 C for the duration of the study. BCX4430 was administered i.m., twice daily (bid) at 300 or 150 mg/kg/d. Ribavirin was given i.p., bid at 75 or 50 mg/kg/ d. Treatments began 4 h prior to virus challenge and continued for 8 days. The identity of the treatment groups was blinded to the technician administering treatments. Mortality was observed twice daily for 28 days, and the weight of each mouse was recorded on day 0 and then every other day from 1 to 19 days post-virus infection (dpi). Mice were humanely euthanized if they could no longer right themselves or were unresponsive to stimuli.
Facilities
Experiments were conducted in the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-accredited and Public Health Service Animal Welfare Assurance-approved Biosafety level-3 animal suite at the Utah State University Laboratory Animal Research Center (LARC). All LARC personnel continually receive special training on blood-borne pathogen handling by the university's Environmental Health and Safety Office.
Statistical analysis
Survival data were analyzed using the Wilcoxon log-rank test and all other statistical analyses were performed using one-way ANOVA using a Bonferroni correction for multiplicity where needed (Prism 7, GraphPad Software, Inc).
Ethics statement
This study, including veterinary care and experimental procedures, was conducted in accordance with the approval of the Institutional Animal Care and Use Committee of Utah State University under the approved protocol #2550.
Results
Evaluation of antiviral compounds in cell culture
In order to determine the activity of the broad-spectrum antiviral agents BCX4430 and ribavirin, activity was initially evaluated using cytopathic effect (CPE) reduction assays and virus yield reduction (VYR) assays. BCX4430 was found to consistently reduce viral CPE induced by Ugandan, Malaysian and Puerto Rican isolates of ZIKV in RD, Huh-7 and Vero76 cell lines with 50% effective concentration (EC 50 ) values in the low mg/ml range and favorable selective index (SI) values (Table 1) . Activity was also similar across the three ZIKV strains tested, representing African, Asian and currently circulating American strains. Activity of BCX4430 was confirmed by VYR tests. The 90% effective concentration (EC 90 ) VYR values were slightly higher but similar to the EC 50 (Table 1) . The VYR concentration-response curves for BCX4430 were similar in the three different cell lines tested (Fig. 1) .
Ribavirin was also active in cell culture, but with variable results depending on the cell line used (Table 1) . Virus yield reduction assays further demonstrated this cell line-dependent variability. Ribavirin was not active against ZIKV infection of Vero76 cells (Fig. 1a) , despite some activity observed in CPE reduction assays. This was unanticipated as Ribavirin has broad-spectrum activity in this cell line against YFV and West Nile virus (WNV) (Julander et al., 2009; Morrey et al., 2002) . Human cell lines, including Huh-7 and RD, confirmed the antiviral activity of Ribavirin (Fig. 1b and c , respectively) and provided support for further studies in animal models.
Establishment of an animal model for ZIKV infection
To further evaluate the effect of BCX4430 and Ribavirin, as well as for use in testing other antivirals and vaccines against ZIKV, we established a model of infection and disease in mice. Wild-type mice typically do not display morbidity or mortality when infected peripherally with ZIKV. For this reason, we selected AG129 mice, which lack type I and type II IFN receptors, due to the susceptible nature of this mouse strain to various viruses (Gowen et al., 2010; Johnson and Roehrig, 1999; Partidos et al., 2011; Thibodeaux et al., 2012) .
A Malaysian strain (P 6-740) of ZIKV was titered in mice (data not shown) and a virus challenge dose of 10 3 pfu/mouse was identified as a suitable dose to cause 100% mortality in AG129 mice after subcutaneous injection (Fig. 2a) . This challenge dose was used in subsequent experiments. Weight declined rapidly just prior to mortality ( Fig. 2b) and coincided with disease signs of infected mice, including conjunctivitis, limb weakness or paralysis, excitability, hunching and lying prone (Fig. 2c) . Infected mice typically displayed one or more symptoms, but the disease signs varied from mouse to mouse. The level of viral RNA accumulation in various tissues was determined by qRT-PCR at various times after infection. Viral RNA levels peaked between 7 and 9 days post-virus inoculation (dpi) and were then cleared from the serum, liver, kidney and uterus (Fig. 2deg) . The peak levels of ZIKV RNA present in serum on 5 and 7 dpi (Fig. 2d) are useful as an antemortem parameter for use in antiviral studies. Viral RNA in the brain, spleen and testis persisted to 13 dpi at relatively high titers (Fig. 2hej) . Viral RNA shedding in the urine was sporadic, although virus was detected as late as 13 dpi (Fig. 2k) . High viral RNA levels in the brain were consistent with neurological disease signs that were observed just prior to mortality. Neurological signs included locomotor hyperactivity (rapid and uncoordinated running around the cage, either spontaneously or upon disturbance), increased respiratory effort, tremor or seizure, and hunching.
Acute multifocal neutrophilic encephalitis with neuronal necrosis was observed in the cerebrum and brain stem (Fig. 3aec,  arrows) . Similar inflammatory lesions were observed in the cerebellum, but were less severe and mainly focused on the Purkinje cells (data not shown). Multifocal neutrophilic myelitis was also present (Fig. 3c, arrowhead) . Immunohistochemical staining confirmed ZIKV infection in motor neurons and astrocytes in AG129 adult mice that exhibited hyperactivity (Fig. 3def) . Various areas of the central nervous system had ZIKV-positive cells, including the cerebral cortex, dentate gyrus, hypoglossal nuclei, solitary nucleus, facial nuclei, paragiganto nucleus, entorhinal cortex, brain stem, and pyramid regions, as well as ventral horn motor neurons of the thoracic and lumbar spinal cord, indicating widespread infection in the central nervous system (Fig. 3dee, arrow) . ZIKV immunoreactivity was also found in male reproductive tissues, including epididymis and testis, particularly in Leydig cells (Fig. 3geh, arrow) . Infectious virus was also detected in various tissues such as testis, brain and kidney (Fig. 3jel ) using immunological staining of Vero76 cells after co-cultivation with tissue homogenates. This method, however, was not quantitative so we report the number of samples that were positive using this assay per total samples processed (Table 2 ). Also reported in Table 2 are the number of samples that contained histological lesions per total observed.
Antiviral efficacy of BCX4430 in vivo
BCX4430 and Ribavirin were evaluated using the AG129 mouse model described above. Each agent was administered for 8 days starting 4 h prior to virus inoculation. All 16 control mice succumbed, with median survival of 15.5 days. Treatment with 300 mg/kg/d of BCX4430 significantly improved survival (median of >28 days, p < 0.001) and protected 7 of 8 mice from mortality ( Fig. 4a ). Mice treated with a lower dose of BCX4430 (150 mg/kg/d) eventually displayed signs of disease and were euthanized; however, there was a significant prolongation of survival (median survival 23 days, p < 0.001) (Fig. 4a) . Ribavirin treatment did not improve outcomes, and at the higher dose of 75 mg/kg/d median survival was 14 days (p < 0.01) (Fig. 4a) . Each mouse was weighed serially between 0 and 19 dpi. Weight of animals treated with 300 mg/kg/d of BCX4430 did not decline substantially during that time (Fig. 4b) and was similar to sham infected animals treated with the same dose of compound (data not shown). ZIKV-infected vehicle treated animals lost weight rapidly in the days prior to mortality, with a mean change of À3.1 ± 2.4 g from days 7e13 (Fig. 4c) , representing the period between peak weight and just prior to the mean day-to-death in the vehicle group. Mean weight change over the same period in mice treated with BCX4430 300 mg/kg/d or 150 mg/kg/d was þ0.2 ± 0.5 and À0.3 ± 0.8 g, respectively (both p < 0.001 compared to vehicle). Ribavirin treatment did not protect against weight loss (Fig. 4c) . The quantification of viral RNA level in serum isolated from ZIKV-infected mice was performed by real-time qRT-PCR.
Comparison of viral RNA level in pooled serum collected on day 5 from ZIKV-infected mice indicated a significant reduction in viremia in groups treated with either dose of BCX4430 (Fig. 4d) . The reduction in viral load appeared to be dose-dependent. Ribavirin treatment did not improve viral RNA levels in the serum (Fig. 4d) , which were consistent with survival data.
Re-challenge of surviving animals
As mentioned above, 7 of 8 mice treated with 300 mg/kg/d of BCX4430 survived ZIKV infection. On day 28 after the initial virus inoculation, these surviving mice were re-challenged with the same challenge dose, route and volume as the initial virus infection. All surviving mice from the initial infection also survived the secondary challenge (Fig. 4e) . Naïve mice that were used as shaminfection controls during the initial phase of the study were also infected on day 28 and succumbed to ZIKV challenge by 23 days after virus challenge as expected (day 51 on Fig. 4e ). High neutralizing antibody titers (4-5 log 10 PRNT 50 ) were present in serum samples taken just prior to re-challenge from BCX4430- Fig. 2 . Survival of ZIKV-infected (n ¼ 9) or sham-infected (n ¼ 4) AG129 mice (a). Weight change of individual mice measured between 0 and 21 dpi (b) and disease signs (c) of AG129 mice infected with ZIKV. Time-course of ZIKV RNA in serum (d), spleen (e), brain (f), liver (g), kidney (h), urine (i), testis (j) and uterus (k) collected at various times after infection. treated mice that survived initial ZIKV challenge (Fig. 4f) . As expected, mice that were initially uninfected did not have detectable levels of ZIKV-neutralizing antibody prior to infection in the rechallenge study (Fig. 4f) .
Therapeutic treatment with BCX4430
A second study was conducted to determine the effect of treatment initiated at various times after ZIKV challenge. A dose of 300 mg/kg/d was given bid for 7 days beginning 1, 3, 5 or 7 dpi. Six of 7 mice were protected from mortality when treatment was initiated 1 day after ZIKV challenge ( Fig. 4g) . Median survival was significantly prolonged in all BCX4430-treated groups, with median survival of >28, 19.5, 18 and 17 days for treatment beginning on days 1, 3, 5 or 7 dpi, respectively (overall p < 0.0001 compared with vehicle), although only a single mouse survived in the day 3 treatment initiation group (Fig. 4g) .
Weights declined as animals became moribund. Significant protection from weight loss between 7 and 13 dpi was observed in mice treated with BCX4430 beginning 1, 3 or 5 dpi, as compared with vehicle control (p < 0.001) (Fig. 4h) . The average percent weight change of animals treated with BCX4430 beginning on 1 dpi remained near baseline, while treatment initiation at progressively later times was associated with earlier declines in weight (Fig. 4i) . The weight change curve of animals treated beginning 7 dpi was similar to that of the vehicle treatment group. Normal control animals gained weight over the course of the study.
Despite improvement in survival and weight change, viral RNA levels in serum on 5 dpi were not significantly decreased in groups treated with BCX4430 beginning 1 or 3 dpi (Fig. 4j) . A progressive decrease in the number of disease signs was observed in the groups with treatment initiated at earlier timepoints, an effect that roughly corresponded to delayed mortality and protection from weight loss (Fig. 4k) .
Discussion
Several models of ZIKV infection in mice have been reported over the last year, mainly in immune deficient mouse strains (Aliota et al., 2016; Rossi et al., 2016; Zmurko et al., 2016) . The AG129 mouse strain was shown to be useful in antiviral studies (Zmurko et al., 2016) . These mice are sensitive to ZIKVinduced disease, but do not succumb until 2e3 weeks after virus challenge, which provides an ample window to test different aspects of antiviral therapy, including post-exposure therapy and identification of compounds that could be used to treat severe outcomes such as encephalitis.
Herein, we characterized the course of ZIKV-induced disease in the AG129 mouse model after exposure with an Asian ZIKV strain. Virus replication in various key organs, including the brain, spinal cord and urogenital tract, provides a sensitive in vivo model that can be used to identify effective treatments and vaccines. ZIKV infection of AG129 mice, however, only models certain aspects of disease since the uniformly lethal phenotype is much more severe than natural infection. Due to the extremely aggressive and fatal course of infection, antiviral therapies must possess potent activity to show benefit in this model. Some differences, such as delayed viremia, were observed as compared with other models described in the literature (Aliota et al., 2016) , but these could be due to differences in detection methods, virus strain used or source of mice.
Severe neurologic manifestations, including excitability with associated tremors, myoclonic twitching, increased respiratory effort and locomotor hyperactivity, were observed in ZIKV-infected adult AG129 mice. During uncoordinated excitable running events, ataxic circling of the cage was usually followed by tremors, often displayed while lying prone. Mortality generally followed 24e48 h after first observing these neurologic signs. Hyperactivity is also observed during infection with borna disease virus, a neurotropic non-cytolytic RNA virus (Hornig et al., 1999) . The infection pattern of ZIKV in the central nervous system was similar to that of the related flavivirus WNV that also infects motor neurons in the ventral horn of spinal cord (Siddharthan et al., 2009 ) and the brain stem , although ZIKV infected cells generally co-localized with astroglial cells while WNV is more neuronspecific. We have also observed a similar infection of astroglial cells after Venezulan equine encephalitis virus infection in a C3H/ HeN mouse model (Julander et al., 2008) .
BCX4430 is a broad-spectrum antiviral that is potently active against a wide variety of RNA viruses including YFV, EBOV and MARV in animal models (Julander et al., 2014; Warren et al., 2014) . The efficacy of BCX4430 in a lethal ZIKV infection described herein represents the first time that protection from ZIKV-associated mortality has been demonstrated in a mouse model. Treatment with another nucleoside analog significantly prolonged median survival time, but did not result in animals surviving infection (Zmurko et al., 2016) . The protective effect of BCX4430 was also observed when treatment was initiated 24 h after virus challenge and significant (P < 0.001) delays in mortality occurred when treatment was delayed as much as 5 dpi, coinciding with peak virus titer in the serum. Ribavirin, another broad-spectrum antiviral that is efficacious in the hamster model of YFV, did not improve outcome from ZIKV infection in AG129 mice. These results further underscore the broad-spectrum efficacy of BCX4430 and provide justification for continued development.
While these studies are important in demonstrating antiviral activity of the compound against ZIKV, the utility of BCX4430 in preventing more serious consequences of ZIKV infection, such as congenital infection and sexual transmission, should be evaluated. There is a precedent in the HIV field for the use of antiviral treatment during pregnancy. Vertical transmission with HIV has been shown to be RNA copy number-dependent, with higher rates occurring with increasing viral loads present in the mother (O'Shea et al., 1998) . Treatment of pregnant women has been demonstrated to drastically reduce the incidence of vertical transmission in women undergoing treatment with a combination of antiretroviral compounds (Cooper et al., 2002) . Treatment, however, may result Table 2 Tissue infectious assay and histopathologic diagnoses of adult AG129 mice infected with ZIKV. in negative outcomes to fetal development and maternal health (Huntington et al., 2015; Papp et al., 2015) . Despite the obvious hurdles associated with the treatment of ZIKV infection in pregnant women, we anticipate there could be an important role played by , weight change between 7 and 13 dpi (c) and viral RNA in pooled (n ¼ 4 per data point) serum on 5 dpi (d) in ZIKV-infected (n ¼ 8) or sham-infected (n ¼ 3) AG129 mice, while ribavirin treatment did not improve any disease parameter. Surviving mice (n ¼ 7) from the initial treatment study with BCX4430 (a) were re-challenged with ZIKV 28 days after the initial viral challenge. Naïve mice that were sham-infected in the first study and treated with either BCX4430 (n ¼ 3) or vehicle (n ¼ 2) were also challenged. Surviving mice did not succumb to the secondary challenge, while naïve animals had a similar mortality curve to the initial study (e). High neutralizing antibody titers were present just prior to re-challenge in the serum of mice that were treated with BCX4430 (n ¼ 7) and survived the initial virus challenge (f). Treatment with BCX4430 was initiated at various times after ZIKV challenge. Survival (g), average weight change between 0 and 28 dpi (h), individual weight change between 7 and 13 dpi (C), mean weight change between 0 and 28 dpi (i), viral RNA from serum on 5 dpi (j) and disease signs (k) observed in BCX4430-treated (n ¼ 8) or vehicle treatment controls (n ¼ 10) infected mice or uninfected, untreated normal control (n ¼ 3) mice were used as disease parameters. Treatment beginning as late as 7 days after virus challenge provided some benefit to ZIKV-infected mice, although survivors were only observed in mice treated beginning 1 or 3 days after ZIKV challenge (***P < 0.001, **P < 0.01, *P < 0.05, as compared with vehicle control).
antiviral therapies and are planning additional murine model studies to delineate the activity of BCX4430 for prevention of congenital infection.
